DC
STML

Deere & Company’s Stemline Therapeutics, Inc. STML Stock Holding History

Deere & Company’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-34,655
Closed -$501K – 1145
2015
Q1 		$501K Buy
+34,655
New +$530K 0.03% 623

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Deere & Company's STML Position: Q2 2015 in Review

Deere & Company sold out of Stemline Therapeutics, Inc. (STML) in Q2 2015, closing a stake of 34,655 shares — an estimated $501K sold.

Deere & Company first reported a position in STML in Q1 2015 and held it in 1 quarter. The position peaked at $501K in Q1 2015. 71 funds tracked by Wall St. Rank hold STML as of Q2 2015.

  • Deere & Company reported no remaining Stemline Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
  • Deere & Company sold 34,655 Stemline Therapeutics, Inc. shares in Q2 2015, an estimated $501K.
  • Deere & Company first reported a position in Stemline Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
  • Deere & Company's Stemline Therapeutics, Inc. position peaked at $501K in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2015.

Based on Deere & Company's 13F filing for Q2 2015, filed 13 Aug 2015.